Drug Trial Radar · NCT00367133
Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Aug 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
840
Actual
Start
Jul 2004
Primary completion
May 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Jaeb Center for Health ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Eye Institute (NEI); Allergan
- First posted
- Aug 22, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study involves the enrollment of patients over 18 years of age with diabetic macular edema(DME). Patients with one study eye will be randomly assigned (stratified by visual acuity and prior laser) with equal probability to one of the three treatment groups: 1. Laser photocoagulation 2. 1mg intravitreal triamcinolone acetonide injection 3. 4mg intravitreal triamcinolone acetonide injection For patients with two study eyes (both eyes eligible at the time of randomization), the right eye (stratified by visual acuity and prior laser) will be randomly assigned with equal probabilities to one of the three treatment groups listed above. The left eye will be assigned to the alternative treatment (laser or triamcinolone). If the left eye is assigned to triamcinolone, then the dose (1mg or 4 mg) will be randomly assigned to the left eye with equal probability (stratified by visual acuity and prior laser). The study drug, triamcinolone acetonide, has been manufactured as a sterile intravitreal injectable by Allergan. Study eyes assigned to an intravitreal triamcinolone injection will receive a dose of either 1mg or 4mg. There is no indication of which treatment regimen will be better. Patients enrolled into the study will be followed for three years and will have study visits every 4 months after receiving their assigned study treatment. In addition, standard of care post-treatment visits will be performed at 4 weeks after each intravitreal injection.
Conditions
- Diabetic Macular Edema
Interventions
Standard of Care GroupProcedure
Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
1mg triamcinolone acetonideDrug
Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
4mg triamcinolone acetonideDrug
4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.Time frame: Baseline to 2 Years
- Median Change in Visual Acuity Baseline to 2 YearsTime frame: Baseline to 2 Years
- Distribution of Change in Visual Acuity Baseline to 2 YearsTime frame: baseline to 2 years
Locations
84 sites in 1 country. Site status is shown where the registry gives one.
Jones Eye Institute/University of Arkansas for Medical Sciences
Little Rock, Arkansas
SCPMG Regional Offices - Kaiser Permanente
Baldwin Park, California
Retina-Vitreous Associates Medical Group
Beverly Hills, California
University of California, Irvine
Irvine, California
Loma Linda University Health Care, Dept. of Ophthalmology
Loma Linda, California
Doheny Eye Institute
Los Angeles, California
Jules Stein Eye Institute
Los Angeles, California
Southern California Desert Retina Consultants, MC
Palm Springs, California
West Coast Retina Medical Group, Inc.
San Francisco, California
Orange County Retina Medical Group
Santa Ana, California
California Retina Consultants
Santa Barbara, California
Bay Area Retina Associates
Walnut Creek, California
Denver Health Medical Center
Denver, Colorado
Eldorado Retina Associates, P.C.
Louisville, Colorado
Connecticut Retina Consultants
New Haven, Connecticut
Connecticut Retina Consultants
New Haven, Connecticut
Retina Group of Florida
Fort Lauderdale, Florida
National Ophthalmic Research Institute
Fort Myers, Florida
Central Florida Retina Institute
Lakeland, Florida
Florida Retina Consultants
Lakeland, Florida
Sarasota Retina Institute
Sarasota, Florida
International Eye Center
Tampa, Florida
Southeast Retina Center, P.C.
Augusta, Georgia
Retina Consultants of Hawaii, Inc.
‘Aiea, Hawaii
Retina Associates of Hawaii, Inc.
Honolulu, Hawaii
Northwestern Medical Faculty Foundation
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Illinois Retina Associates
Joliet, Illinois
Raj K. Maturi, M.D., P.C.
Indianapolis, Indiana
John-Kenyon American Eye Institute
New Albany, Indiana
Retina and Vitreous Associates of Kentucky
Lexington, Kentucky
Paducah Retinal Center
Paducah, Kentucky
Maine Vitreoretinal Consultants
Bangor, Maine
Elman Retina Group, P.A.
Baltimore, Maryland
Wilmer Ophthalmological Institute at Johns Hopkins
Baltimore, Maryland
The Retina Group of Washington
Greenbelt, Maryland
Retina Consultants of Delmarva, P.A.
Salisbury, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
Joslin Diabetes Center
Boston, Massachusetts
Kresge Eye Institute
Detroit, Michigan
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.